Emend 3-Day Side Effects

Generic Name: aprepitant

Note: This document contains side effect information about aprepitant. Some of the dosage forms listed on this page may not apply to the brand name Emend 3-Day.

Some side effects of Emend 3-Day may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.

For the Consumer

Applies to aprepitant: oral capsule

Along with its needed effects, aprepitant (the active ingredient contained in Emend 3-Day) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking aprepitant:

Less common
  • Black or tarry stools
  • chills
  • cough
  • fever
  • lower back or side pain
  • painful or difficult urination
  • pale skin
  • shortness of breath
  • sore throat
  • ulcers, sores, or white spots in the mouth
  • unusual bleeding or bruising
  • unusual tiredness or weakness
Incidence not known
  • Blistering, peeling, or loosening of the skin
  • confusion about identity, place, and time
  • diarrhea
  • itching
  • joint or muscle pain
  • large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs
  • redness of the skin
  • red, irritated eyes
  • red skin lesions, often with a purple center
  • skin rash
  • slow or irregular heartbeat

Some side effects of aprepitant may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common
  • Acid or sour stomach
  • belching
  • confusion
  • decreased urination
  • dizziness
  • dry mouth
  • fainting
  • heartburn
  • hiccups
  • increase in heart rate
  • indigestion
  • lack or loss of strength
  • lightheadedness
  • loss of appetite
  • nausea
  • rapid breathing
  • stomach discomfort upset or pain
  • sunken eyes
  • swelling or inflammation of the mouth
  • thirst
  • weight loss
  • wrinkled skin
Less common
  • Burning feeling in the chest or stomach
  • hot flashes
  • indigestion
  • pain or discomfort in the chest, upper stomach, or throat
  • tenderness in the stomach area

For Healthcare Professionals

Applies to aprepitant: oral capsule, oral kit

Cardiovascular

Cardiovascular side effects including deep vein thrombosis, hypertension, hypotension, myocardial infarction, pulmonary embolism, and tachycardia have been reported with the use of aprepitant (the active ingredient contained in Emend 3-Day) as a part of a regimen that also included ondansetron and dexamethasone which was given along with highly emetogenic cancer chemotherapy.

Dermatologic

Dermatologic side effects including alopecia (24%) and rash have been reported with the use of aprepitant (the active ingredient contained in Emend 3-Day) as a part of a regimen that also included ondansetron and dexamethasone which was given along with moderately or highly emetogenic cancer chemotherapy. Postmarketing side effects reported include pruritus, rash, urticaria, and rarely Stevens-Johnson syndrome/toxic epidermal necrolysis.

Gastrointestinal

Gastrointestinal side effects including nausea (7.1% to 12.7%), constipation (10.3% to 12.3%), diarrhea (5.5% to 10.3%), dyspepsia (8.4%), vomiting (7.5%), stomatitis (5.3%), heartburn (5.3%), gastritis (4.2%), and epigastric discomfort (4.0%) have been reported with the use of aprepitant (the active ingredient contained in Emend 3-Day) as a part of a regimen with ondansetron and dexamethasone which was given along with moderately or highly emetogenic cancer chemotherapy. Acid reflux, deglutination, disorder, dysgeusia, dysphagia, flatulence, obstipation, increased salivation, and taste disturbance have also been reported.

General

General side effects including asthenia/fatigue (17.8%), dizziness (3.4% to 6.6%), dehydration (5.9%), abdominal pain (4.6%), fever (2.9%), mucous membrane disorder (2.6%) have been reported with the use of aprepitant (the active ingredient contained in Emend 3-Day) as a part of a regimen that also included ondansetron and dexamethasone which was given along with moderately or highly emetogenic cancer chemotherapy. Diaphoresis, edema, flushing, malaise, pelvic pain, septic shock, and upper respiratory infection have also been reported. The most common side effects reported at an incidence of 1% or greater were hiccups, asthenia/fatigue, increased ALT, increased AST, constipation, dyspepsia, diarrhea, headache, and anorexia.

Genitourinary

Genitourinary side effects including dysuria and renal insufficiency have been reported with the use of aprepitant (the active ingredient contained in Emend 3-Day) as a part of a regimen that also included ondansetron and dexamethasone which was given along with highly emetogenic cancer chemotherapy.

Hematologic

Hematologic side effects including neutropenia have been reported with the use of aprepitant (the active ingredient contained in Emend 3-Day) as a part of a regimen that also included ondansetron and dexamethasone which was given along with highly emetogenic cancer chemotherapy. Anemia, febrile neutropenia, and thrombocytopenia have also been reported.

Hypersensitivity

Hypersensitivity side effects including anaphylactic reactions have been reported.

Metabolic

Metabolic side effects including diabetes mellitus have been reported with the use of aprepitant (the active ingredient contained in Emend 3-Day) as a part of a regimen that also included ondansetron and dexamethasone which was given along with highly emetogenic cancer chemotherapy. Decreased appetite, hypokalemia, and weight loss have also been reported.

Musculoskeletal

Musculoskeletal side effects including muscular weakness, musculoskeletal pain, and myalgia have been reported with the use of aprepitant (the active ingredient contained in Emend 3-Day) as a part of a regimen that also included ondansetron and dexamethasone which was given along with highly emetogenic cancer chemotherapy.

Nervous system

Nervous system side effects including headache (8.5% to 16.4%) and insomnia (2.9%) have been reported with the use of aprepitant (the active ingredient contained in Emend 3-Day) as a part of a regimen that also included ondansetron and dexamethasone which was given along with highly emetogenic cancer chemotherapy. Peripheral neuropathy and sensory neuropathy have also been reported.

Other

Other side effects including anorexia (4.3% to 10.1%) and tinnitus (3.7%) have been reported with the use of aprepitant (the active ingredient contained in Emend 3-Day) as a part of a regimen that also included ondansetron and dexamethasone which was given along with moderately or highly emetogenic cancer chemotherapy.

Oncologic

Thyroid follicular cell adenomas and carcinomas in male rats and increased incidences of hepatocellular adenoma and thyroid follicular adenoma in female rats have been reported. The drug has also been reported to cause skin fibrosarcomas in male mice.

Oncologic side effects including malignant neoplasm and non-small cell lung carcinoma have been reported with the use of aprepitant as a part of a regimen that also included ondansetron and dexamethasone which was given along with highly emetogenic cancer chemotherapy.

Psychiatric

Psychiatric side effects including anxiety disorder, confusion, and depression have been reported with the use of aprepitant (the active ingredient contained in Emend 3-Day) as a part of a regimen that also included ondansetron and dexamethasone which was given along with highly emetogenic cancer chemotherapy.

Respiratory

Respiratory side effects including hiccups (10.8%) have been reported with the use of aprepitant (the active ingredient contained in Emend 3-Day) as a part of a regimen that also included ondansetron and dexamethasone which was given along with moderately or highly emetogenic cancer chemotherapy. Cough, dyspnea, pneumonitis, respiratory insufficiency, lower respiratory infection, nasal secretion, pharyngitis, pharyngolaryngeal pain, and vocal disturbance have also been reported.

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.

Advanced Breast Cancer: Learn about treatments to improve quality of life. Click Here

Close
Hide
(web1)